MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Chorea (also see specific diagnoses, Huntingtons disease, etc): Treatment"

  • 2023 International Congress

    Effectiveness of deep brain stimulation in the treatment of Huntington’s disease

    H. Rodrigues, G. Mantovani, M. da Rosa, V. de Souza, L. Aires, M. Fin, L. Lobato, R. Albuquerque, PL. da Silva, A. Hilbig (Porto Alegre, Brazil)

    Objective: The aim is to obtain relevant information regarding the effectiveness of using Deep Brain Stimulation (DBS) as a treatment of Huntington's disease (HD). Background:…
  • 2023 International Congress

    Crushing valbenazine capsule contents for potential addition to soft foods or administration via G tube

    M. Hebert, A. Mar, R. Moore, A. Bristow, S. Siegert (San Diego, USA)

    Objective: To evaluate the suitability of mixing crushed contents from valbenazine capsules with soft foods/liquids or adding them to water for delivery through a gastrostomy…
  • 2023 International Congress

    Chorea improvements over time with once-daily valbenazine treatment in adults with Huntington disease

    E. Furr Stimming, E. Kayson, J. Goldstein, H. Zhang, O. Klepitskaya, G. Liang, D. Haubenberger (Houston, USA)

    Objective: To describe the effects of valbenazine (VBZ) over time on chorea in adults with Huntington disease (HD). Background: The Ph3 KINECTTM-HD (NCT04102579) trial met…
  • 2022 International Congress

    Baseline Characteristics and Treatment Patterns of a Global Huntington Disease Population Stratified by Chorea Severity

    V. Sung, E. Furr Stimming, S. Reshef, R. Willock, R. Ribalov, S. Brighton, S. Leo (Birmingham, USA)

    Objective: To describe baseline characteristics and treatment patterns in patients with chorea associated with Huntington disease (HD) by severity of chorea. Background: Though multiple treatment…
  • 2022 International Congress

    4 YEARLONG POST PARTUM AUTOIMMUNE CHOREA AS INITIAL PRESENTATION OF INCOMPLETE SLE/APS

    W. Trillo Alvarez, J. Medina Suárez, J. Molina Acosta, A. Escalante Mercado, C. Ibañez Escalante, E. Carrillo Monteagudo, V. Medina Cerpa, E. Ramos Luza, P. Gonzales Romero, G. García Huamán (AREQUIPA, Peru)

    Objective: The aim is to report a case of a 4 yearlong postpartum autoimmune chorea secondary to incomplete SLE/APS. Background: Chorea is a movement disorder…
  • 2022 International Congress

    Real-World Treatment Patterns and Outcomes in Patients With Chorea Associated With Huntington Disease Using Tetrabenazine or Deutetrabenazine in Combination with Antipsychotic Drugs

    D. Claassen, H. Romdhani, R. Ayyagari, D. Goldschmidt, S. Zoye Moroz, A. Hernandez, S. Leo (Nashville, USA)

    Objective: To describe treatment patterns with vesicular monoamine transporter 2 inhibitors (VMAT2i; tetrabenazine [TBZ], or deutetrabenazine [DTBZ]) in combination with antipsychotic agents (APs) in patients…
  • 2022 International Congress

    Clinical and biomarker characteristics of Huntington’s Disease patients recently proposed for huntingtin-lowering clinical trial inclusion

    G. Parkin, E. Thomas, C. Snell, A. Smirnova, A. Hall, L. Bohall, E. Churchill, J. Corey-Bloom (Irvine, USA)

    Objective: We investigated plasma NfL levels, as well as clinical measures, in Huntingtin (Htt)-mutation carriers 48 years of age and under, with a CAP score…
  • 2022 International Congress

    The START Study: A Phase 4 Study on the Real-World Utilization of Deutetrabenazine Initiated by a 4-Week Patient Titration Kit

    K. Anderson, M. Konings, S. Finkbeiner, A. Cutler (Washington, USA)

    Objective: To assess the real-world utilization of deutetrabenazine (DTBZ) for the treatment of tardive dyskinesia (TD) or chorea associated with Huntington disease (HD) initiated by…
  • 2022 International Congress

    Contemporary study of the difficulties of late diagnostics in patients with Huntington’s disease in Uzbekistan

    G. Goyibova, S. Kuranbaeva, A. Umarov, S. Kalandarova (Tashkent, Uzbekistan)

    Objective: To identify the causes that lead to late diagnosis of Huntington's disease. Background: Huntington's disease is a rare, progressive, and fatal autosomal dominant neurodegenerative…
  • 2022 International Congress

    A randomized, sham-controlled, crossover trial on Transcranial pulsed current stimulation (tPCS) in Huntington disease

    M. Tuesta Bernaola, Y. Tamilselvam, Y. Mahdi, J. Ganguly, D. Aur, M. Jog (London, Canada)

    Objective: 1. To assess brain network level dysfunction of Huntington disease (HD). 2.  To evaluate the effectiveness of 2-week home-based chronic non-invasive transcranial brain stimulation (NIBS) in…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 9
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Safety and Tolerability of a Ketone Supplement in Parkinson's Disease
  • Successful external defibrillation in a patient with bilateral deep brain stimulation
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Life expectancy with and without Parkinson’s disease in the general population
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley